Abstract:Neuroinflammation is an important contributor to Alzheimer's disease (AD) pathogenesis, as underscored by the recent identification of immune-related genetic risk factors for AD, including coding variants in the gene TREM2 (triggering receptor expressed on myeloid cells 2). Understanding TREM2 function promises to provide important insights into how neuroinflammation contributes to AD pathology. However, studies so far have produced seemingly conflicting results, with reports that amyloid pathology can be both decreased and increased in TREM2-deficient AD mouse models. In this study, we unify these previous findings by demonstrating that TREM2 deficiency ameliorates amyloid pathology early, but exacerbates it late in disease progression in the APPPS1–21 mouse model of AD. We also demonstrate that TREM2 deficiency decreases plaque-associated myeloid cell accumulation by reducing cell proliferation, specifically late in pathology. In addition, TREM2 deficiency reduces myeloid cell internalization of amyloid throughout pathology, but decreases inflammation-related gene transcript levels selectively late in disease progression. Together, these results suggest that TREM2 plays distinct functional roles at different stages in AD pathology.SIGNIFICANCE STATEMENT Alzheimer's disease (AD) is a devastating neurodegenerative disorder and there are currently no effective treatments that modify disease progression. However, the recent identification of genetic risk factors for AD promises to provide new insight into AD biology and possible new therapeutic targets. Among these risk factors, variants in the gene TREM2 (triggering receptor expressed on myeloid cells 2) confer greatly elevated risk for developing the disease. We demonstrate that TREM2 deficiency has opposing effects on AD-related pathologies at early and late stages of disease progression, unifying previous work in the field. In addition, we examine how TREM2 affects the function of the brain immune cell populations in which it is expressed throughout disease progression to understand possible mechanisms underlying its differential impacts on pathology.

Loss of TREM2 reduces hyperactivation of progranulin deficient microglia but not lysosomal pathology

Loss of TREM2 rescues hyperactivation of microglia, but not lysosomal deficits and neurotoxicity in models of progranulin deficiency

TREM2 expression level is critical for microglial state, metabolic capacity and efficacy of TREM2 agonism

TREM2 Regulates Microglial Cholesterol Metabolism Upon Chronic Phagocytic Challenge

Elevating Microglia TREM2 Reduces Amyloid Seeding and Suppresses Disease-Associated Microglia

Enhancing protective microglial activities with a dual function TREM2 antibody to the stalk region

Defects in lysosomal function and lipid metabolism in human microglia harboring a TREM2 loss of function mutation

Gene expression and functional deficits underlie TREM2-knockout microglia responses in human models of Alzheimer’s disease

Neutral or Detrimental Effects of TREM2 Agonist Antibodies in Preclinical Models of Alzheimers Disease and Multiple Sclerosis

TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer’s disease mouse models

TREM2 interacts with TDP-43 and mediates microglial neuroprotection against TDP-43-related neurodegeneration

Opposing Roles of the Triggering Receptor Expressed on Myeloid Cells 2 and Triggering Receptor Expressed on Myeloid Cells-Like Transcript 2 in Microglia Activation.

Trem2-deficiency aggravates and accelerates age-related myelin degeneration

Microglia, Trem2, and Neurodegeneration

Established Beta Amyloid Pathology Is Unaffected by TREM2 Elevation in Reactive Microglia in an Alzheimer’s Disease Mouse Model

TREM2 drives microglia response to amyloid-β via SYK-dependent and -independent pathways

TREM2 regulates microglial lipid droplet formation and represses post-ischemic brain injury

Alzheimer's disease‐associated R47H TREM2 increases, but wild‐type TREM2 decreases, microglial phagocytosis of synaptosomes and neuronal loss

TREM2 Regulates Microglial Phagocytosis of Synapses in Innate Immune Tolerance

TREM2 Maintains Microglial Metabolic Fitness in Alzheimer’s Disease

Disease Progression-Dependent Effects of TREM2 Deficiency in a Mouse Model of Alzheimer's Disease